original articlesthoracic tumorsPhase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer
thoracic tumors
Under an Elsevier user license
open archive
Key words
disease control rate
erlotinib
everolimus
non-small-cell lung cancer
progression-free survival
stomatitis
Cited by (0)
Copyright © 2014 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.